Colon Cancer
Conditions
Brief summary
Creation of a prospective clinico-biological database dedicated to cachexia and undernutrition in order to carry out future research projects, to improve our knowledge of colon cancer and cachexia and to optimize the therapeutic management of patients
Detailed description
Patients with cancers, and in particular colorectal cancers, very often present profound nutritional and/or metabolic alterations, the most spectacular being cachexia. Cachexia is a morbid syndrome characterized by rapid involuntary weight loss mainly affecting the storage tissues of adipose tissue and skeletal muscle. This global metabolic syndrome is a major contributory factor and sometimes causative factor in the failure of treatments and the death of patients. Although a major public health problem, this disease is poorly understood and for which there are no reliable biomarkers and no universally accepted treatment protocol. It therefore appears essential to better understand this disease in order to improve the well-being and survival of patients. Being a disease with a strong metabolic component, the integration of nutritional approaches is essential. Many advances have been made in recent years in the field of clinical nutrition, particularly in cancer cachexia. Clinical nutrition is a new, transversal, booming specialty. Recent publications suggests that cancer patients, overweight or obese, may present muscle depletion, an independent predictor of overall survival. Recent results suggest that muscle atrophy is associated with more severe toxicity of anti-cancer treatments such as fluoropyrimidines, anthracyclines, combination chemotherapy, sunitinib and sorafenib. Muscle wasting is a predictive factor for therapeutic dose limitation: dose reduction, delay or definitive discontinuation of treatment. The majority of anti-cancer drugs have a limited therapeutic index. It is important to determine the factors that explain the individual variations in efficacy and toxicity, and the determination of body composition for each patient is therefore an important step in the nutritional evaluation process, and essential data for this data base. The investigators therefore propose the development of a prospective clinico-biological database for cachexia in patients with colon cancer, can be used for research projects aimed at developing tailored patient management strategies.
Interventions
BIOLOGICALBiological collection
\- Blood samples collected at different times: at inclusion and during treatment ( every 6 month)
Sponsors
Institut du Cancer de Montpellier - Val d'Aurelle
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years old, 2. Patient treated at the Montpellier Regional Cancer Institute for colon cancer not eligible for surgery (of the primary tumor or associated metastases), whether undergoing treatment or not, 3. Patient requiring treatment for colon cancer (chemotherapy, targeted therapy, etc.), 4. Patient having accepted the constraints of the research and the blood samples planned for the research 5. Patient affiliated to Social Protection system 6. Informed consent form signed
Exclusion criteria
1. Patient requiring surgery (for treatment of colon cancer or metastasis) 2. Patient with exclusive peritoneal carcinomatosis 3. Patient requiring radiotherapy 4. Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons 5. Pregnant and/ or breastfeeding women 6. Patient cared for an emergency context
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of clinical risk factors for colorectal cancer | Until the study completion : 6 years |
| Number of biological risk factors for colorectal cancer | Until the study completion : 6 years |
Countries
France
Contacts
Primary ContactJean-Pierre Bleuse, MD
Backup ContactAurore Moussion
Outcome results
None listed